Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
This is a Phase 4, multicenter, prospective and retrospective, long-term observational study of Avonex® and Rebif® to determine the efficacy, tolerability, and safety in subjects with relapsing MS.
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have been receiving AVONEX® or Rebif®.
Must have a confirmed diagnosis of relapsing-remitting MS using the Poser criteria.
Must have experienced at least 2 relapses within the 3 year period prior to the initiation of treatment.
Must have an EDSS score of 0.0 to 5.5, inclusive.
You may not be if
History of severe allergic or anaphylactic reaction or hypersensitivity to human albumin, to any interferon, or to other components of the drug formulation.
History of poorly controlled hypertension and/or other clinically significant major disease.
History of uncontrolled seizures within the 3 months prior to enrollment.
History of suicidal ideation or an episode of severe depression within the 3 months prior to enrollment.
Serious local infection or systemic infection within 8 weeks prior to enrollment.
Treatment with certain other agents to treat MS symptoms or underlying disease.
Treatment with any investigational product
Previous participation in this study.
Clareo Health | Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
